Bupropion/zonisamide

Drug Profile

Bupropion/zonisamide

Alternative Names: Bupropion SR/zonisamide IR; Bupropion SR/zonisamide SR; Empatic™; Excalia™; Zonisamide IR/bupropion SR; Zonisamide SR/bupropion SR; Zonisamide/bupropion

Latest Information Update: 01 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orexigen Therapeutics
  • Class Antidepressants; Antiepileptic drugs; Isoxazoles; Obesity therapies; Propiophenones; Sulfonamides
  • Mechanism of Action Adrenergic uptake inhibitors; Antioxidants; Calcium channel antagonists; Dopamine release stimulants; Dopamine uptake inhibitors; Neuron inhibitors; Serotonin release stimulants; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 20 Mar 2013 Bupropion/Zonisamide is available for licensing as of 20 Mar 2013. www.orexigen.com
  • 30 Sep 2009 Efficacy and adverse events data from a phase IIb trial in obesity released by Orexigen Therapeutics
  • 09 Oct 2008 Data from two post-hoc analyses from a phase IIb trial in Obesity presented at the 2008 Obesity Society Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top